Work

Olanzapine with or without an NK-1 receptor antagonist for preventing chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy: A phase III randomized, double-blind, placebo-controlled trial (ALLIANCE A221602).

Year: 2022

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2022.40.16_suppl.12107

Authors: Rudolph M. Navari, Jennifer Le-Rademacher, Fabrice Smieliauskas, Kathryn Jean Ruddy, Thomas James Saphner, Heshan Liu, Beth Harlos, Adedayo A. Onitilo, Karthik Giridhar, Preet Paul Singh, Pavan S. Reddy, Flavio Kruter, George Raptis, Charles L. Loprinzi

Institutions: Mayo Clinic, University of Chicago, Mayo Clinic Comprehensive Cancer Center (Minnesota), Marshfield Clinic Weston Center, Cancer Center of Kansas, Carroll Hospital, Northwell Health

Language: English

Topic: Nausea and vomiting management

Subfield: Surgery

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: National Institutes of Health

OpenAlex ID: W4286296457

Cites:

Cited by: 1

Related to: 10